CD8A and neoplasm: Multiple studies show that targeting MDSC leads to an improvement in anti-tumor immunity, specifically recovery of CD8+ T cell anti-tumor activity, resulting in tumor suppression, and multiple modes of targeting MDSC are in clinical development.